scott storer  general electric company  zoominfocom scott storer profiles  facebook facebookemail or phonepasswordforgot accountenglish usespañolfrançais franceالعربيةportuguês brasilitaliano한국어deutschहिन्दीmessengerfacebook litepeopleplacesgameslocationscelebritiesmarketplacegroupsrecipesmomentsinstagramaboutcreate adcreate pagedeveloperscareersprivacycookiesad choicestermssettingsactivity log facebook     momenta pharmaceuticals appoints scott m storer as senior vice president and chief financial officer  pt community skip to main content pt community registersign in search form search home news ptcurrent issue past issues masthead digital edition subscribe pt tv authors about contact us   ingrezza® valbenazine tablets‎ zurampic® lesinurad tabletsplease click for full prescribing information including boxed warning you are herehome momenta pharmaceuticals appoints scott m storer as senior vice president and chief financial officer cambridge mass nov   globe newswire  momenta pharmaceuticals inc nasdaqmnta a biotechnology company specializing in the characterization and engineering of complex drugs today announced the appointment of scott m storer as senior vice president and chief financial officer mr storer is expected to begin at momenta on november   and will replace momenta’s current chief financial officer rick shea who will be retiring mr storer will report directly to craig wheeler momenta’s president and chief executive officer and will serve as a member of the executive committee “i am very pleased to have scott join momenta he has a great track record across his  years with baxter and baxalta and i believe his expertise in financial planning and leading global strategic growth initiatives and operations will benefit momenta tremendously” said craig wheeler president and ceo momenta pharmaceuticals “with the addition of scott’s leadership i look forward to continuing to advance the development and commercialization of our robust portfolio of biosimilar and novel drug candidates” prior to joining momenta mr storer was senior vice president finance at baxalta inc following its spinout from baxter international in july 5 previously mr storer held several positions with baxter most recently serving as vice president of bioscience finance where he provided financial leadership internal controls and business partnership to the bioscience us commercial organization global manufacturing rd business development and all support functions before that he held positions of increasing responsibility at several of baxter’s international finance divisions mr storer began his work at baxter as a financial analyst in  he received a master’s in business administration from northwestern university’s kellogg school of management and a bachelor of science degree in business administration from the university of colorado at boulder about momentamomenta pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex drugs and is headquartered in cambridge ma momenta is applying its technology to the development of generic versions of complex drugs biosimilar and potentially interchangeable biologics and to the discovery and development of novel therapeutics for autoimmune indications to receive additional information about momenta please visit the website at wwwmomentapharmacom which does not form a part of this press release our logo trademarks and service marks are the property of momenta pharmaceuticals inc all other trade names trademarks or service marks are property of their respective owners forward looking statements statements in this press release regarding managements future expectations beliefs intentions goals strategies plans or prospects are forwardlooking statements within the meaning of the private securities litigation reform act of  including but not limited to statements about mr storer’s expected start date and the expected benefits from his service to the company forwardlooking statements may be identified by words such as anticipate believe continue could hope target project goal objective guidance plan potential predict might estimate expect intend may seek should will would look forward and other similar words or expressions or the negative of these words or similar words or expressions such forwardlooking statements involve known and unknown risks uncertainties and other factors including those referred to under the section risk factors in the companys quarterly report on form q for the quarter ended june   filed with the securities and exchange commission as well as other documents that may be filed by the company from time to time with the securities and exchange commission as a result of such risks uncertainties and factors the companys actual results may differ materially from any future results performance or achievements discussed in or implied by the forwardlooking statements contained herein the company is providing the information in this press release as of this date and assumes no obligations to update the information included in this press release or revise any forwardlooking statements whether as a result of new information future events or otherwise contact investor contact sarah carmody momenta pharmaceuticals 675 irmomentapharmacom media contact karen sharma macdougall biomedical communications 76 momentamacbiocomcom wednesday november     stay in touch newsletters available pt and drug management daily news pt table of contents monthly contact us editorial j stephen mciver editoradvertising maureen dwyer liberti vice president group publisherproduction dawn flook director of production servicescirculation jackie ott circulation managerwebmaster webmaster industry announcements affimed presents data on firstinclass bcmatargeting immune cell engager afm6 at asco annual meeting  share buyback week  novartis drug tasigna receives eu approval for inclusion of treatmentfree remission tfr data in product label basilea announces presentation of interim phase a clinical data with anticancer drug candidate bal55 at asco meeting targovax presents further positive clinical data from tg phase iii trial at  asco annual meeting addex annual general meeting scheduled for  june  valneva to present at jefferies  global healthcare conference in new york targovax announces formal agenda for  capital markets updates in oslo and london lundbeck obtains rights to breakthrough research in alzheimer’s disease veloxis pharmaceuticals as announces agreement with chiesi farmaceutici spa to commercialize envarsus xr in china more from globe newswire current issue of pt july  user login username  password  create new account request new password scott m storer  senior vice president chief financial officer  treasurer at momenta pharmaceuticals inc news home advertising board and executive moves energy health care hedge funds m  a private equity technology you have    free profiles   left this month    start your free trial ➤ hey we noticed youre a relsci pro subscriber would you like to view the page there view on relsci pro ➤ email linkedin facebook google tweet reddit permalink scott m storer senior vice president chief financial officer  treasurer at momenta pharmaceuticals inc overview in the news relationships paths education career history boards  committees public holdings scott m storer senior vice president chief financial officer  treasurer at momenta pharmaceuticals inc overview age 4 born 75 notable companies momenta pharmaceuticals inc board seats  number of relationships this person is connected to 4 people in the news see more relsci july   scott m storer is now serving in a new position at momenta pharmaceuticals inc globenewswire november   momenta pharmaceuticals reports third quarter  financial results relationships see details craig a wheeler president  chief executive officer at momenta pharmaceuticals inc ganesh venkataraman kaundinya cofounder at momenta pharmaceuticals inc john k clarke cofounder at cardinal partners alan crane cofounder at arsia therapeutics richard p shea chief financial officer  treasurer at syndax pharmaceuticals inc bruce a leicher former general counsel senior vice president  secretary at momenta pharmaceuticals inc santiago arroyo chief medical officer  senior vice president development at momenta pharmaceuticals inc bruce l downey partner at newspring capital jim sulat professional at valneva se georges gemayel former executive vice presidenttherapeutics  biosurgery at sanofi genzyme see 4 more listings with relsci professional start my free trial ➤ see 4 more paths to scott m storer scott m storer you connections via relationship science scott m storer sync your contacts to see how you can connect with scott m storer start my free trial ➤ see more educational background   northwestern university  kellogg school of management the kellogg school of management the kellogg school or kellogg is the business school of northwestern university in evanston illinois with additional campuses in downtown chicago illinois and miami florida kellogg offers fulltime parttime and executive programs and partners with schools in china francesingapore india hong kong israel germany canada and thailandfounded in  in downtown chicago as a parttime evening program the school was chartered to educate business leaders with good moral character   university of colorado  boulder as the flagship university of the state of colorado cuboulder is a dynamic community of scholars and learners situated on one of the most spectacular college campuses in the country as one of 4 us public institutions belonging to the prestigious association of american universities aau – and the only member in the rocky mountain region – we have a proud tradition of academic excellence with five nobel laureates and more than  members of prestigious academic academies cuboulder has blossomed in size and quality since we opened our doors in 77 – attracting superb faculty staff and students and building strong programs in the sciences engineering business law arts humanities education music and many other disciplines today with our sights set on becoming the standard for the great comprehensive public research universities of the new century we strive to serve the people of colorado and to engage with the world through excellence in our teaching research creative work and service career history senior vice president chief financial officer  treasurer   current momenta pharmaceuticals inc momenta is a leader in the analysis characterization and design of complex pharmaceutical products our scientific foundation is a set of tools and methods that enable one to develop a deep understanding of the links between a compound’s chemical structure its manufacturing process and its biological function these innovative tools enable us to develop complex generics and followon biologics as well as facilitate the discovery of novel drugs we believe that by applying our innovative technology to our discovery and development programs we have the potential to create a robust pipeline of innovative generic and novel drugs our success is a result of our committed and talented people we attract scientists exceptionally skilled in integrating information from diverse technical disciplines and task them with challenging characterization process and biology problems using this approach we have designed tools and methods to understand the structure characterization of chemical components structureprocess design and control of manufacturing process and structureactivity relationships between structure and biological and clinical activity of complex mixture drugs from this knowledge comes a diversified product development pipeline consisting of both generic and novel complex mixture drugs designed to address a variety of medical needs in july  momenta announced the fda approval of our first drug enoxaparin sodium injection developed in collaboration with sandoz enoxaparin is a more affordable generic version of lovenox® enoxaparin sodium injection which is indicated for the prophylaxis of deep vein thrombosis dvt enoxaparin sodium injection is a heparinbased complex mixture drug that was developed using our innovative scientific approach following this initial success we are applying a similar approach to developing a generic version of copaxone® glatiramer acetate a complex mixture of polypeptides indicated for the treatment of relapsingremitting multiple sclerosis we are also adding followon biologics which are highly similar and potentially interchangeable biologics to our development pipeline and finally with the knowledge acquired from our complex generic and followon biologics business we are our using our tools and technology to design and improve the structures of proteins and heparinderived products to create novel drugs boards  committees corporate boards ▾ member executive committee   current momenta pharmaceuticals inc momenta is a leader in the analysis characterization and design of complex pharmaceutical products our scientific foundation is a set of tools and methods that enable one to develop a deep understanding of the links between a compound’s chemical structure its manufacturing process and its biological function these innovative tools enable us to develop complex generics and followon biologics as well as facilitate the discovery of novel drugs we believe that by applying our innovative technology to our discovery and development programs we have the potential to create a robust pipeline of innovative generic and novel drugs our success is a result of our committed and talented people we attract scientists exceptionally skilled in integrating information from diverse technical disciplines and task them with challenging characterization process and biology problems using this approach we have designed tools and methods to understand the structure characterization of chemical components structureprocess design and control of manufacturing process and structureactivity relationships between structure and biological and clinical activity of complex mixture drugs from this knowledge comes a diversified product development pipeline consisting of both generic and novel complex mixture drugs designed to address a variety of medical needs in july  momenta announced the fda approval of our first drug enoxaparin sodium injection developed in collaboration with sandoz enoxaparin is a more affordable generic version of lovenox® enoxaparin sodium injection which is indicated for the prophylaxis of deep vein thrombosis dvt enoxaparin sodium injection is a heparinbased complex mixture drug that was developed using our innovative scientific approach following this initial success we are applying a similar approach to developing a generic version of copaxone® glatiramer acetate a complex mixture of polypeptides indicated for the treatment of relapsingremitting multiple sclerosis we are also adding followon biologics which are highly similar and potentially interchangeable biologics to our development pipeline and finally with the knowledge acquired from our complex generic and followon biologics business we are our using our tools and technology to design and improve the structures of proteins and heparinderived products to create novel drugs public holdings restricted data only for relsci professional users start my free trial ➤ see more other affiliations scott m storer is affiliated with momenta pharmaceuticals inc momenta pharmaceuticals inc youve reached your  free profiles limit this month upgrade to relsci pro today to enjoy unlimited article views and much more start my free trial ➤ still not convinced check out our full listing of features here are you a relsci pro subscriber login to relsci pro  ➤ not a pro subscriber log in here to manage your alerts keep me signed in login  ➤ forgot your password i have read the lexisnexis terms  conditions sign me up  ➤ microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext7 personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft scott m storer is now serving in a new position at momenta pharmaceuticals inc news home advertising board and executive moves energy health care hedge funds m  a private equity technology see more news on board and executive moves scott m storer is now serving in a new position at momenta pharmaceuticals inc email linkedin facebook google tweet reddit permalink jul    relsci data update board and executive moves background information scott m storer » senior vice president chief financial officer  treasurer at momenta pharmaceuticals inc career momenta pharmaceuticals inc boards momenta pharmaceuticals inc education northwestern university  kellogg school of management university of colorado  boulder in the news momenta pharmaceuticals reports third quarter  financial results november    •  globenewswire scott m storer » senior vice president chief financial officer  treasurer at momenta pharmaceuticals inc career • momenta pharmaceuticals inc boards • momenta pharmaceuticals inc education • northwestern university  kellogg school of management • university of colorado  boulder in the news momenta pharmaceuticals reports third quarter  financial results  november    •  globenewswire momenta pharmaceuticals inc » momenta is a leader in the analysis characterization and design of complex pharmaceutical products our scientific foundation is a set of tools and methods that enable one to develop a deep understanding of the links between a compound’s chemical structure its manufacturing process and its biological function these innovative tools enable us to develop complex generics and followon biologics as well as facilitate the discovery of novel drugs we believe that by applying our innovative technology to our discovery and development programs we have the potential to create a robust pipeline of innovative generic and novel drugs our success is a result of our committed and talented people we attract scientists exceptionally skilled in integrating information from diverse technical disciplines and task them with challenging characterization process and biology problems using this approach we have designed tools and methods to understand the structure characterization of chemical components structureprocess design and control of manufacturing process and structureactivity relationships between structure and biological and clinical activity of complex mixture drugs from this knowledge comes a diversified product development pipeline consisting of both generic and novel complex mixture drugs designed to address a variety of medical needs in july  momenta announced the fda approval of our first drug enoxaparin sodium injection developed in collaboration with sandoz enoxaparin is a more affordable generic version of lovenox® enoxaparin sodium injection which is indicated for the prophylaxis of deep vein thrombosis dvt enoxaparin sodium injection is a heparinbased complex mixture drug that was developed using our innovative scientific approach following this initial success we are applying a similar approach to developing a generic version of copaxone® glatiramer acetate a complex mixture of polypeptides indicated for the treatment of relapsingremitting multiple sclerosis we are also adding followon biologics which are highly similar and potentially interchangeable biologics to our development pipeline and finally with the knowledge acquired from our complex generic and followon biologics business we are our using our tools and technology to design and improve the structures of proteins and heparinderived products to create novel drugs in the news santiago arroyo is now serving in a new position at momenta pharmaceuticals inc june    •  relsci momenta pharmaceuticals appoints santiago arroyo md phd as chief medical officer june    •  globenewswire how these generic drugs stocks are faring  akorn collegium pharma momenta pharma and diplomat pharmacy may 5   •  pr newswire momenta pharmaceuticals inc » momenta is a leader in the analysis characterization and design of complex pharmaceutical products our scientific foundation is a set of tools and methods that enable one to develop a deep understanding of the links between a compound’s chemical structure its manufacturing process and its biological function these innovative tools enable us to develop complex generics and followon biologics as well as facilitate the discovery of novel drugs we believe that by applying our innovative technology to our discovery and development programs we have the potential to create a robust pipeline of innovative generic and novel drugs our success is a result of our committed and talented people we attract scientists exceptionally skilled in integrating information from diverse technical disciplines and task them with challenging characterization process and biology problems using this approach we have designed tools and methods to understand the structure characterization of chemical components structureprocess design and control of manufacturing process and structureactivity relationships between structure and biological and clinical activity of complex mixture drugs from this knowledge comes a diversified product development pipeline consisting of both generic and novel complex mixture drugs designed to address a variety of medical needs in july  momenta announced the fda approval of our first drug enoxaparin sodium injection developed in collaboration with sandoz enoxaparin is a more affordable generic version of lovenox® enoxaparin sodium injection which is indicated for the prophylaxis of deep vein thrombosis dvt enoxaparin sodium injection is a heparinbased complex mixture drug that was developed using our innovative scientific approach following this initial success we are applying a similar approach to developing a generic version of copaxone® glatiramer acetate a complex mixture of polypeptides indicated for the treatment of relapsingremitting multiple sclerosis we are also adding followon biologics which are highly similar and potentially interchangeable biologics to our development pipeline and finally with the knowledge acquired from our complex generic and followon biologics business we are our using our tools and technology to design and improve the structures of proteins and heparinderived products to create novel drugs in the news santiago arroyo is now serving in a new position at momenta pharmaceuticals inc  june    •  relsci momenta pharmaceuticals appoints santiago arroyo md phd as chief medical officer  june    •  globenewswire how these generic drugs stocks are faring  akorn collegium pharma momenta pharma and diplomat pharmacy  may 5   •  pr newswire see more news on board and executive moves youve found a premium relsci pro feature connect to individuals and organizations in this story upgrade to relsci pro to easily sync your contacts and see how you can reach the people and organizations featured in this article start my free trial ➤ still not convinced check out our full listing of features here not now are you a relsci pro subscriber login to relsci pro  ➤ not a pro subscriber log in here to manage your alerts keep me signed in login  ➤ forgot your password i have read the lexisnexis terms  conditions sign me up  ➤   homeworking with us working with us it starts with you for us success is about helping you reach your goals not a number see how we work life priority tool assessment tool ml® solutions about ml® your life priorities your life priorities what’s important to you you have priorities and we have the insights you need to keep them front and center see how finances home health family leisure giving work research  insights our insights a real advantage industryleading research and expert analysis are here to help you stay ahead explore our insights markets people innovation government earth find an advisor get the right guidance for you connect with an advisor and start a conversation about your goals contact a financial advisor not who youre looking for get to know some of our other financial advisors find another advisor search by name search by location search by linkedin your recently viewed advisor visit our page find an advisor contact us client login merrill lynch financial advisor scott a storer  global wealth management senior financial advisorsenior vice president e bidwell suite folsom  ca  56get directions phone 6 45 email  learn more about an advisor’s background on finra’s brokercheck client commitment scott storer is registered to do business in  az ca co dc hi il in la mi mn nc nj nv ny ok or pa tx ut va wa for questions regarding registration information please contact your financial advisor top information for corporations  institutions job seekers media  journalists shareholders discover merrill lynch about us working with us our solutions research  insights merrill lynch social media get in touch contact us66 am  pm est monfri connect with us flipboard linkedin twitter youtube site map privacy  security legal information mlpfs financial brokercheck investing in securities involves risks and there is always the potential of losing money when you invest in securities neither merrill lynch nor any of its affiliates or financial advisors provide legal tax or accounting advice you should consult your legal andor tax advisors before making any financial decisions asset allocation diversification and rebalancing do not ensure a profit or protect against loss in declining markets investment products insurance and annuity products are not fdic insured are not bank guaranteed may lose value are not deposits are not insured by any federal government agency are not a condition to any banking service or activity merrill lynch makes available products and services offered by merrill lynch pierce fenner  smith incorporated mlpfs a registered brokerdealer and member securities investor protection corporation sipc and other subsidiaries of bank of america corporation insurance and annuity products are offered through merrill lynch life agency inc a licensed insurance agency and wholly owned subsidiary of bank of america corporation merrill lynch is the marketing name for merrill lynch wealth management and merrill edge® both of which are made available through merrill lynch pierce fenner  smith incorporated mlpfs merrill edge is available through merrill lynch pierce fenner  smith incorporated mlpfs and consists of the merrill edge advisory center investment guidance and selfdirected online investing trust and fiduciary services are provided by us trust a division of bank of america na member fdic or us trust company of delaware both are wholly owned subsidiaries of bank of america corporation banking products are provided by bank of america na and affiliated banks members fdic and wholly owned subsidiaries of bank of america corporation mlpfs and us trust make available investment products sponsored managed distributed or provided by companies that are affiliates of bank of america corporation or in which bank of america corporation has a substantial economic interest  bank of america corporation all rights reserved e7d scb momenta pharmaceuticals appoints scott m storer as senior vice president and chief financial officer  thestreet action alerts plus access aapjim cramers best stocks for charitable trust portfoliomost recent trade alert5 investing rules trading commandments real money access rm5 rules of investingjim cramers best stocks for  commandmentsstressed out stockscramers blog cramer mad money etfs futures markets much more banksbiotechretailtechpersonal financeretirementfinancial advisor centerhow to spendoptionsfixed incomevideo privacy policyterms of use 6 thestreet inc all rights reserved djia nasdaq sp 5 market data updated sign in your memberships your account account preferences alerts newsletters subscribe logout subscribe access insights and guidance from our wall street pros find the product thats right for you action alerts plus action alerts options daily swing trade income seeker quant ratings real money real money pro stocks under  top stocks trifecta stocks real money pro portfolio chairmans club compare all chatter on the street momenta pharmaceuticals appoints scott m storer as senior vice president and chief financial officer globenewswire nov    am edt cambridge mass nov   globe newswire  momenta pharmaceuticals inc nasdaqmnta a biotechnology company specializing in the characterization and engineering of complex drugs today announced the appointment of scott m storer as senior vice president and chief financial officer mr storer is expected to begin at momenta on november   and will replace momentas current chief financial officer rick shea who will be retiring mr storer will report directly to craig wheeler momentas president and chief executive officer and will serve as a member of the executive committee i am very pleased to have scott join momenta he has a great track record across his  years with baxter and baxalta and i believe his expertise in financial planning and leading global strategic growth initiatives and operations will benefit momenta tremendously said craig wheeler president and ceo momenta pharmaceuticals with the addition of scotts leadership i look forward to continuing to advance the development and commercialization of our robust portfolio of biosimilar and novel drug candidates prior to joining momenta mr storer was senior vice president finance at baxalta inc following its spinout from baxter international in july 5 previously mr storer held several positions with baxter most recently serving as vice president of bioscience finance where he provided financial leadership internal controls and business partnership to the bioscience us commercial organization global manufacturing rd business development and all support functions before that he held positions of increasing responsibility at several of baxters international finance divisions mr storer began his work at baxter as a financial analyst in  he received a masters in business administration from northwestern universitys kellogg school of management and a bachelor of science degree in business administration from the university of colorado at boulder about momentamomenta pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex drugs and is headquartered in cambridge ma momenta is applying its technology to the development of generic versions of complex drugs biosimilar and potentially interchangeable biologics and to the discovery and development of novel therapeutics for autoimmune indications to receive additional information about momenta please visit the website at  wwwmomentapharmacom which does not form a part of this press release our logo trademarks and service marks are the property of momenta pharmaceuticals inc all other trade names trademarks or service marks are property of their respective owners if you liked this article you might like drug price inflation and a patent cliff could trigger a wave of deals in generic drugs space generic drugmakers are likely to limit themselves to acquisitions of small and midsized companies in the immediate future because of overleveraging and turmoil in the executive ranks william mcconnell jun   7 pm edt analysts actions  discovery first solar momenta vf corp and more here are wednesdays top research calls including downgrades for discovery first solar and momenta and an upgrade for vf corp thestreet staff feb    am est sarepta leads biotech movers on voucher deal news gilead finally has acquired something from sarepta even if it is quite small alicia mcelhaney feb    am est mylans shares rise despite ftc investigation the drug company saw its stock climb  tuesday on news that it can move ahead with generic copaxone alicia mcelhaney jan   6 am est advertising partners 6 thestreet inc all rights reservedaction alerts plus is a registered trademark of thestreet inc compare brokers